Yiguanjian cataplasm attenuates opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome

被引:0
作者
Gao Shuai [1 ]
Gao Hong [2 ]
Fan Yuchen [1 ,3 ]
Zhang Guanghua [2 ]
Sun Fengkai [1 ]
Zhao Jing [1 ]
Li Feng [1 ]
Yang Yang [1 ]
Wang Kai [1 ,3 ]
机构
[1] Department of Hepatology,Qilu Hospital of Shandong University
[2] Institute of Hepatology,Shandong University
[3] Research Center for Material Evidence Identification,Shandong Public Security Bureau
关键词
Yi Guan Jian; Paste; Morphine; Nalox one; Opioid dependence;
D O I
暂无
中图分类号
R285.5 [中药实验药理];
学科分类号
1008 ;
摘要
OBJECTIVE:To investigate the effect of Yiguanjian(YGJ) cataplasm on the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.METHODS:One hundred Swiss albino mice,of equal male to female ratio,were randomly and equally divided into 10 groups.A portion(3 cm2) of the backside hair of the mice was removed 1 day prior to the experiment.Morphine(5 mg/kg) was intraperitoneally administered twice daily for 5days.YGJ cataplasm was prepared and pasted on the bare region of the mice immediately beforemorphine administration on day 3 and subsequently removed at the end day 5.On day 6,naloxone(8mg/kg) was intraperitoneally injected to precipitate opioid withdrawal syndrome.Behavioral observation was performed in two 30-min phases immediately after naloxone injection.RESULTS:The YGJ cataplasm significantly and dose-dependently attenuated morphine-naloxone-induced experimental opioid withdrawal,in terms of withdrawal severity score and the frequencies of jumping,rearing,forepaw licking,and circling behaviors.However,YGJ cataplasm treatment did not alter the acute analgesic effect of morphine.CONCLUSION:YGJ cataplasm could attenuate opioid dependence and its associated withdrawal symptoms.Therefore,YGJ cataplasm could serve as a potential therapy for opioid addiction in the future.
引用
收藏
页码:464 / 470
页数:7
相关论文
共 36 条
  • [31] Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence
    Walker, EA
    Sterious, SN
    BRITISH JOURNAL OF PHARMACOLOGY, 2005, 145 (07) : 975 - 983
  • [32] NALOXONE-INDUCED ANOREXIA INCREASES NEUROPEPTIDE-Y CONCENTRATIONS IN THE DORSOMEDIAL HYPOTHALAMUS - EVIDENCE FOR NEUROPEPTIDE-Y OPIOID INTERACTIONS IN THE CONTROL OF FOOD-INTAKE
    LAMBERT, PD
    WILDING, JPH
    ALDOKHAYEL, AAM
    GILBEY, SG
    GHATEI, MA
    BLOOM, SR
    PEPTIDES, 1994, 15 (04) : 657 - 660
  • [33] Pharmacokinetic Modeling and Model-Based Hypothesis Generation for Dose Optimization of Clonidine in Neonates With Neonatal Opioid Withdrawal Syndrome
    Tang, Fei
    Ng, Chee M.
    Horn, Jamie
    Bada, Henrietta S.
    Leggas, Markos
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, : 1254 - 1263
  • [34] Neuron Type-Dependent Synaptic Activity in the Spinal Dorsal Horn of Opioid-Induced Hyperalgesia Mouse Model
    Kearns, Austin
    Jayasi, Jazmine
    Liu, Xin
    Wang, Jigong
    Shi, Yuqiang
    Chung, Jin Mo
    La, Jun-Ho
    Tang, Shao-Jun
    Bae, Chilman
    FRONTIERS IN SYNAPTIC NEUROSCIENCE, 2021, 13
  • [35] OPIOID ANTAGONISTS NALOXONE, BETA-FUNALTREXAMINE AND NALTRINDOLE, BUT NOT NOR-BINALTORPHIMINE, REVERSE THE INCREASED HINDPAW WITHDRAWAL LATENCY IN RATS INDUCED BY INTRATHECAL ADMINISTRATION OF THE CALCITONIN-GENE-RELATED PEPTIDE ANTAGONIST CGRP(8-37)
    YU, LC
    HANSSON, P
    LUNDEBERG, T
    BRAIN RESEARCH, 1995, 698 (1-2) : 23 - 29
  • [36] A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain
    Edwards, Katie A.
    Havelin, Joshua J.
    Mcintosh, Mary I.
    Ciccone, Haley A.
    Pangilinan, Kathlene
    Imbert, Ian
    Largent-Milnes, Tally M.
    King, Tamara
    Vanderah, Todd W.
    Streicher, John M.
    JOURNAL OF PAIN, 2018, 19 (06) : 612 - 625